SecBot SecBot
6-K ·Filed Nov 3, 2026

SOPH

SOPHiA GENETICS SA
NEUTRAL
Impact 5/10
Horizonmonths Processed14d 8h ago SEC0001840706-26-000350
6-K: Earnings release
Actionable Insight • Neutral

The company's improving adjusted EBITDA trajectory and narrowing guidance suggest a path toward breakeven in H2 2027. Monitor the Guardant Health litigation outcome in the U.K. and any drawdown of the remaining $25M Perceptive credit facility, which would add leverage but also fund growth.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

SOPHiA GENETICS reported Q3 2026 revenue of $24.3M, up 25% YoY, and a net loss of $20.3M, roughly flat YoY. The company guided full-year 2026 revenue to the upper end of its $94M-$96M range and narrowed adjusted EBITDA loss guidance to $29M-$32M, improving from $41.5M in FY 2025. Key operating metrics strengthened: platform analysis volume grew 19% YoY, net dollar retention improved to 118% from 108%, and core genomics customers reached 551.

Key Financial Metrics

EPS
−$0.24
Revenue
$24.3M
est $24.0M · +1.1% · +24.7% YoY
Guidance
$94M-$96M (upper end)
maintained
Gross Margin
65.7%

Key Facts

  • Q3 2026 revenue $24.3M, up 25% YoY from $19.5M
  • Net loss $20.3M vs $20.0M in Q3 2025, essentially flat
  • SOPHiA DDM Platform revenue $23.8M, up 27% YoY
  • Platform analysis volume 117,639, up 19% YoY
  • Net dollar retention 118% vs 108% a year ago
  • Core genomics customers 551 vs 488 a year ago
  • Adjusted EBITDA loss improved 31% YoY to $6.1M
  • Full-year 2026 revenue guidance narrowed to upper end of $94M-$96M
  • Adjusted EBITDA loss guidance $29M-$32M vs $41.5M in FY 2025
  • Cash and cash equivalents $93.7M as of Sep 30, 2026
  • Guardant Health litigation ongoing; UPC Court of Appeal confirmed no provisional injunction in July 2026
  • Signed 30 new core genomics customers in Q3 2026

Financial Impact

Revenue growth of 25% YoY to $24.3M; net loss unchanged at ~$20M; adjusted EBITDA loss improved 31% to $6.1M

revenuenet lossadjusted EBITDAcash burn

Segment Breakdown

SegmentRevenueGrowth
SOPHiA DDM Platform$23.8M+27.2%
Workflow equipment and services$517.0K-35.0%

Risk Factors

  • Guardant Health patent litigation in the U.K. and EU remains pending; adverse ruling could block MSK-ACCESS commercialization
  • Foreign exchange headwinds noted as a potential drag on Q4 2026 revenue
  • Company still loss-making with operating cash burn of $32.3M in 9M 2026
  • Potential loss of emerging growth company status by Dec 31, 2026, increasing compliance costs
  • High share-based compensation ($12.4M in 9M 2026) and social charges ($5.1M) weigh on reported results

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Processing & Data Preparation
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001840706-26-000350
Document: sophiageneticssaex992q32026.htm0001840706-26-000350
Document: sophiageneticssaex993q32026.htm0001840706-26-000350
Document: q32026sophiageneticssa6-k.htm0001840706-26-000350
Document: 0001840706-26-000350-index-headers.html0001840706-26-000350
Document: 0001840706-26-000350-index.html0001840706-26-000350
Document: 0001840706-26-000350.txt0001840706-26-000350
Earnings Context (Synthetic; results releases only)0001840706-26-000350

Track record

47 reports on SOPH

Performance horizon

5 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +64.11% at T+60 after the Jun 4, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $7.45 Now $7.45 −0.00% settles Nov 25
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $7.44 Now $7.45 +0.13% settles Nov 24
  3. Nov 12, 20265d ago Insider Cluster Mixed 4/10 Entry $8.21 Now $7.45 −9.26% settles Nov 20
  4. Nov 12, 20265d ago SC 13D/A Neutral 3/10 Entry $7.86 Now $7.45 −5.22% settles Nov 19
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
  6. Nov 9, 20268d ago Insider Cluster Bullish 4/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
  7. Nov 3, 202614d ago 6-K Neutral 5/10 Viewing No price data
  8. Nov 3, 202614d ago Press Release Neutral 5/10 Entry $6.91 to $7.86 Now $7.45 +7.81% ▲ +13.75% +14.34% vs SPY
  9. Oct 14, 20264w ago Insider Cluster Neutral 2/10 Entry $7.29 to $7.05 Now $7.45 +2.19% ▼ −3.29% −2.28% vs SPY
  10. Oct 5, 20266w ago 144 Neutral 2/10 Entry $7.38 to $7.09 Now $7.45 +0.95% ▼ −3.93% −3.79% vs SPY
Showing 10 of 47

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026